- Home
- NUVL vs VOYA Comparison
NUVL vs VOYA Comparison
Compare NUVL & VOYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- VOYA
- Stock Information
- Founded
- NUVL 2017
- VOYA 1975
- Country
- NUVL United States
- VOYA United States
- Employees
- NUVL N/A
- VOYA N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- VOYA Life Insurance
- Sector
- NUVL Health Care
- VOYA Finance
- Exchange
- NUVL Nasdaq
- VOYA Nasdaq
- Market Cap
- NUVL 6.7B
- VOYA 6.7B
- IPO Year
- NUVL 2021
- VOYA 2013
- Fundamental
- Price
- NUVL $87.30
- VOYA $68.21
- Analyst Decision
- NUVL Strong Buy
- VOYA Buy
- Analyst Count
- NUVL 10
- VOYA 12
- Target Price
- NUVL $112.60
- VOYA $86.00
- AVG Volume (30 Days)
- NUVL 350.8K
- VOYA 835.9K
- Earning Date
- NUVL 11-12-2024
- VOYA 02-04-2025
- Dividend Yield
- NUVL N/A
- VOYA 2.65%
- EPS Growth
- NUVL N/A
- VOYA 3.27
- EPS
- NUVL N/A
- VOYA 6.28
- Revenue
- NUVL N/A
- VOYA $7,859,000,000.00
- Revenue This Year
- NUVL N/A
- VOYA N/A
- Revenue Next Year
- NUVL N/A
- VOYA $6.88
- P/E Ratio
- NUVL N/A
- VOYA $10.84
- Revenue Growth
- NUVL N/A
- VOYA 10.94
- 52 Week Low
- NUVL $61.80
- VOYA $63.11
- 52 Week High
- NUVL $113.51
- VOYA $84.30
- Technical
- Relative Strength Index (RSI)
- NUVL 36.14
- VOYA 20.00
- Support Level
- NUVL $84.64
- VOYA $81.41
- Resistance Level
- NUVL $89.31
- VOYA $83.59
- Average True Range (ATR)
- NUVL 2.82
- VOYA 1.49
- MACD
- NUVL -0.72
- VOYA -1.49
- Stochastic Oscillator
- NUVL 20.93
- VOYA 1.91
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About VOYA Voya Financial Inc.
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.